Get the Daily Brief
Latest Biotech News
Chan Zuckerberg Initiative and Columbia Develop AI Virtual Human Cell Model
Researchers at Columbia University and the Chan Zuckerberg Initiative (CZI) introduced GREmLN, an AI-based virtual human cell model designed to predict cellular state transitions in health and...
Radiopharmaceutical Biotechs Nuclidium and Actithera Secure Major Funding
Two European radiopharmaceutical companies are advancing their clinical and development programs with significant funding rounds. Nuclidium AG raised $99 million in Series B financing to progress...
Advancements in Cancer Liquid Biopsy using Microbiome-Derived RNA Modifications
University of Chicago scientists have developed a novel liquid biopsy test that utilizes low-input multiple methylation sequencing (LIME-seq) to detect RNA modifications in plasma cell-free RNA...
Merck Makes $10 Billion Bet on COPD With Verona Pharma Acquisition
Merck & Co. has agreed to acquire London-based Verona Pharma for $10 billion, centered on the recently approved COPD drug Ohtuvayre. The FDA approved Ohtuvayre in June 2024 as the first inhaled...
FDA Publishes Drug Rejection Letters in Historic Transparency Move
The U.S. Food and Drug Administration has taken a historic step by releasing an initial batch of more than 200 drug rejection letters, referred to as complete response letters (CRLs). These...
Actithera Raises $75.5 Million Series A to Advance Radiopharmaceutical Cancer Drug
Radiopharmaceutical startup Actithera has secured $75.5 million in Series A funding to propel clinical development of a novel treatment targeting fibroblast activation protein (FAP) expressed in...
Personalis and Tempus Expand Partnership for Cancer MRD Detection
Personalis has extended its strategic collaboration with Tempus AI to broaden commercialization of the NeXT Personal minimal residual disease (MRD) assay into colorectal cancer, adding to prior...
Revolution Medicines, Iambic Team Up for AI-Driven Cancer Drug Discovery
Oncology-focused Revolution Medicines has initiated a multi-year collaboration with AI drug discovery firm Iambic Therapeutics worth up to $25 million. Iambic will train its NeuralPLexer...
Chan Zuckerberg Initiative and Columbia Researchers Develop AI Virtual Cell Model GREmLN
A novel AI model named GREmLN (Gene Regulatory Embedding-based Large Neural model) has been developed by Columbia University and Chan Zuckerberg Initiative researchers to improve predictions of...
AbbVie Acquires Ichnos Glenmark’s Trispecific Antibody for Multiple Myeloma
AbbVie has agreed to pay $700 million upfront to acquire rights to ISB 2001, a trispecific antibody developed by Ichnos Glenmark Therapeutics targeting multiple myeloma. The antibody engages CD3...
Aqtual Secures $31 Million Series B to Advance Rheumatoid Arthritis Therapy Selection Assay
Precision medicine startup Aqtual has raised $31 million in an oversubscribed Series B financing to support commercialization of its cell-free DNA-based assay predicting patient response to...
Soleno Therapeutics’ Rare Disease Drug Vykat XR Sales Outpace Expectations
Soleno Therapeutics reported second-quarter sales of Vykat XR, its rare disease drug approved for Prader-Willi syndrome, significantly exceeding analyst forecasts with $31-33 million in revenue....
Merck Bets $10B on Verona Pharma’s COPD Drug
Merck & Co. announced a $10 billion acquisition of London-based Verona Pharma, securing the fast-growing inhaled therapy Ohtuvayre (ensifentrine) for chronic obstructive pulmonary disease (COPD)....
FDA Publishes Historic Drug Rejection Letters with Caveats
For the first time, the FDA released over 200 rejection letters sent to drugmakers concerning novel and generic drug applications. This unprecedented transparency initiative, covering decisions...
Renasant Bio Rises with $54M Seed to Target Kidney Disease
Renasant Bio, a Berkeley-based biotech aiming to develop corrector and potentiator medicines for autosomal dominant polycystic kidney disease (ADPKD), has raised $54.5 million in a seed round. The...
Actithera Raises $75M in Radiopharmaceutical Series A Round
Radiopharmaceutical biotech Actithera successfully closed a $75.5 million Series A financing to advance its cancer drug pipeline targeting fibroblast activation protein (FAP). Despite operating as...
Aqtual Secures $31M Series B to Advance Rheumatoid Arthritis Test
Precision medicine startup Aqtual raised $31 million in an oversubscribed Series B round to develop its cell-free DNA-based assay designed to predict patient response to rheumatoid arthritis...
AI, Gene Editing Merge to Accelerate Drug Development
Recent discussions highlight the growing role of artificial intelligence in transforming traditionally artisanal, trial-and-error drug development into more rapid, cost-effective, and data-driven...
University of Chicago Develops RNA Modification-Based Colorectal Cancer Liquid Biopsy
Researchers at the University of Chicago developed a liquid biopsy diagnostic based on microbiome-derived cell-free RNA modification patterns that can detect colorectal cancer (CRC) with higher...
Chan Zuckerberg Initiative Launches GREmLN AI Model to Advance Cancer Immunotherapy
The Chan Zuckerberg Initiative unveiled GREmLN, an AI model designed to capture complex gene regulatory networks in single-cell RNA data using graph-based neural networks. Developed by Andrea...